e-Drug3D

606

ISRADIPINE


INN
ISRADIPINE

cas 75695-93-1
CLASS

CARDIOVASCULAR
CA CHANNEL ANTAGONIST
ANTIHYPERTENSIVE
VASODILATOR AGENTS

ROUTE (list)

ORAL

ATC code

C08CA03

PK parameters

F 19.5 PERCENT
Tmax 1.5 HOUR
VD 195 LITER (65 KILOGRAM)
Cl 84 LITER / HOUR
PPB 95 PERCENT
t1/2 8 HOUR

Solubility

PRACTICALLY INSOLUBLE IN WATER


Target

TARGET VOLTAGE-DEPENDENT CALCIUM CHANNEL

DrugCentral

Voltage-dependent L-type calcium channel subunit alpha-1C UNIPROT Q13936 CACNA1C

Voltage-dependent L-type calcium channel subunit alpha-1D UNIPROT Q01668 CACNA1D

Download SDF file O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

Formula:
C19H21N3O5

Calculated chemical properties:

MW 371.39
NB_atoms 27
XLogP 2.58
PSA 90.521
NB_HD 1
NB_HA 8
fsp3 0.37
Lipinski(0=no;1=yes) 1

FDA
NDA 019546 (pdf not found) INN (ISRADIPINE) DYNACIRC (SMITHKLINE BEECHAM) APPROVAL= AP YEAR= 1990 DISCONTINUED
NDA 020336 (pdf not found) INN (ISRADIPINE) DYNACIRC CR (GLAXOSMITHKLINE LLC) APPROVAL= AP YEAR= 1994 DISCONTINUED
NDA 077169 (pdf not found) INN (ISRADIPINE) ISRADIPINE (ELITE LABS INC) APPROVAL= AP YEAR= 2006
NDA 077317 (pdf not found) INN (ISRADIPINE) ISRADIPINE (WATSON LABS TEVA) APPROVAL= AP YEAR= 2006
NDA 201067 (pdf not found) INN (ISRADIPINE) ISRADIPINE (NORVIUM BIOSCIENCE) APPROVAL= AP YEAR= 2015 DISCONTINUED

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL